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A B S T R A C T
Skin is an attractive but also very challenging immunisation site for particulate subunit vaccines. The aim of this
study was to develop hyaluronan (HA)-based dissolving microneedles (MNs) loaded with PLGA nanoparticles
(NPs) co-encapsulating ovalbumin (OVA) and poly(I:C) for intradermal immunisation. The NP:HA ratio used for
the preparation of dissolving MNs appeared to be critical for the quality of MNs and their dissolution in ex vivo
human skin. Asymmetrical ﬂow ﬁeld-ﬂow fractionation and dynamic light scattering were used to analyse the
NPs released from the MNs in vitro. Successful release of the NPs depended on the drying conditions during MN
preparation. The delivered antigen dose from dissolving MNs in mice was determined to be 1 µg OVA, in NPs or
as free antigen, by using near-infrared ﬂuorescence imaging. Finally, the immunogenicity of the NPs after ad-
ministration of dissolving MNs (NP:HA weight ratio 1:4) was compared with that of hollow MN-delivered NPs in
mice. Immunization with free antigen in dissolving MNs resulted in equally strong immune responses compared
to delivery by hollow MNs. However, humoral and cellular immune responses evoked by NP-loaded dissolving
MNs were inferior to those elicited by NPs delivered through a hollow MN. In conclusion, we identiﬁed several
critical formulation parameters for the further development of NP-loaded dissolving MNs.
1. Introduction
Skin is an attractive site for vaccination because of its rich network
of immune cells and its accessibility [1]. However, the top layer of the
skin, the stratum corneum, eﬀectively prevents the penetration of
vaccines into the skin. Conventional needles can be used for in-
tradermal immunizations but this method is painful and technically
challenging. Therefore, vaccination via the skin requires the develop-
ment of a device that enables pain-free administration of vaccines into
the epidermis and dermis, which both harbour a dense network of
immune cells (e.g. Langerhans cells and dermal dendritic cells) [2].
Among several developed devices for intradermal vaccine administra-
tion, microneedles (MN) are currently one of the most promising
technologies. They are needle-like structures with micron-scale lengths
(< 1000 µm) typically assembled as arrays with the ability to pierce
into the skin in a minimally invasive and pain-free manner [3,4].
In modern vaccine programmes, subunit antigens (e.g., proteins) are
preferred since they can oﬀer safer and better controlled alternatives to
whole vaccines [5,6]. However, frequently the immunogenicity of plain
subunit antigens is limited. Therefore, subunit vaccines typically con-
tain adjuvants, such as an optimally designed delivery system and an
immune modulator. Several types of nanocarriers have been examined
for vaccine delivery and of those polymeric nanoparticles (NP) and li-
posomes are most commonly used [7–9]. Particle-based vaccines can
improve the immune responses against the antigen due to their re-
semblance to pathogens, prolonged release of antigen and possibility to
tailor particle properties depending on the required type of immune
response [5,8,10]. In addition, particulate formulations allow the co-
delivery of antigen and adjuvant and enhanced uptake in DCs, which
can further enhance the immunogenicity of the antigen against in-
fectious diseases [11–13] or cancer [14–16]. However, the skin is still
rarely used as non-invasive administration route for particulate vac-
cines. The major challenges are reproducible delivery of a suﬃcient
dose of particulate vaccines into the skin and simultaneous the mini-
mization of the fabrication wastage of the vaccine.
Arrays of dissolving [17,18] and coated MNs [19] are dry-state MN
technologies that have been used to deliver NP vaccines into the skin. In
dissolving MNs, nanoparticles are localized in the MN matrix, and after
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the MN array is inserted into the skin, the MNs dissolve, thereby re-
leasing the NPs. Beside dry-state MNs, single hollow MN can be used to
inject NP suspensions into the skin without time-consuming develop-
ment of dissolving or coated MN formulations. Therefore, it is an ideal
tool to compare vaccine formulations for intradermal delivery [20].
The advantages of dissolving MNs are that the use of dry vaccine
formulations can potentially increase the stability and eliminate the
need for a cold chain, in contrast to hollow MNs which require a liquid
formulation [21,22]. In addition, dissolving MNs are prepared from safe
and biodegradable materials and do not create sharp waste in contrast
to coated MNs [4]. Until now, a limited number of studies have been
reported on NP-based intradermal vaccination using dissolving MNs
[17,18]. Particularly, the formulation development of NP-loaded dis-
solving MNs has not been described in detail in the literature. More-
over, studies on the eﬀect of the MN composition and the NP in-
corporation on the preparation and MN dissolution have not been
reported yet. Finally, the quantiﬁcation of the intradermally delivered
antigen dose are only reported for coated MNs [23]. Challenging factors
for developing dissolving MNs include the need for (1) reproducible MN
penetration into the skin, (2) dissolution and subsequent release of NPs
from the MNs into the skin, (3) delivery of a suﬃcient and reproducible
antigen dose and (4) minimizing the loss of often expensive antigen and
adjuvant.
The aim of this study was to develop NP-loaded dissolving MNs to
evoke humoral and cellular immune responses after intradermal vac-
cination. Poly(lactic-co-glycolic) acid (PLGA) NPs co-encapsulating
model antigen ovalbumin (OVA) and TLR3 ligand poly(I:C) as adjuvant
were selected. Dissolving MNs were prepared from hyaluronan (HA)
and contained PLGA NPs that were loaded exclusively into the MN tips.
Next, the most suitable formulation composition (i.e., the weight ratio
of HA and NPs) and preparation conditions for MN dissolution was
evaluated by using ex vivo human skin. Using the optimized MN com-
position, we quantiﬁed the delivered dose in mice. Finally, dissolving
and hollow MN-mediated intradermal immunization with PLGA NPs
were compared for the ability to evoke humoral and cellular immune
responses in mice.
2. Materials and methods
2.1. Materials
Hyaluronan (sodium hyaluronate, average Mw was 150 kDa) was
purchased from Lifecore Biomedical (Chaska, MN, USA). Alexa Fluor
647® NHS ester (AF647) was purchased from Life Technologies
(Eugene, OR, USA). IRDye® 800CW protein labelling kit was ordered
from LI-COR Biosciences (Lincoln, NE, USA). Polydimethylsiloxane
(PDMS, Sylgard 184) was obtained from Dow Corning (Midland, MI,
USA). Solid silicon MN arrays were kindly provided by the Tyndall
Institute (Cork, Ireland). PLGA (50/50, acid terminated, Mw
24–38 kDa), ovalbumin for in vitro and ex vivo studies, bovine serum
albumin (BSA), ﬂuoresceinamine (isomer I, FAM), polysorbate 80
(Tween 80) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Ethyl acetate was obtained from Boom Chemicals (Meppel, The
Netherlands). Polyvinyl alcohol 4–88 (PVA, 31 kDa) was ordered from
Fluka (Steinheim, Germany). Dimethylsulfoxide (DMSO) was ordered
from Biosolve BV (Valkenswaard, The Netherlands). Sodium dodecyl
sulfate (SDS) from Merck Millipore (Hohenbrunn, Germany).
Ovalbumin (Endoﬁt, endotoxin-free), polyinosinic-polycytidylic acid
(poly(I:C)) (low molecular weight) and rhodamine-labelled poly(I:C)
were obtained from Invivogen (Toulouse, France). HRP-conjugated
goat anti-mouse IgG1 and IgG2a were purchased from Southern Biotech
(Birmingham, AL, USA). 3,3′,5,5′-tetra methyl benzidine (1-Step Ultra
TMB) was ordered from ThermoScientiﬁc (Rockford, IL, USA).
Fluorescently labeled antibodies speciﬁc for CD4, CD8, Thy1.2 and
CD45.1 were ordered from eBioscience (San Diego, CA, USA). The
Cytoﬁx solution for T-cell analysis was purchased from BD Biosciences
(San Jose, CA, USA). Cell culture medium consisted of Roswell Park
Memorial Institute medium (RPMI) with 10% Fetal bovine serum (FBS),
1% L-glutamine and 1% Penicillin-streptamycin. FACS buﬀer was pre-
pared by diluting 2% FBS in PBS.
2.2. PLGA nanoparticle preparation
The PLGA NPs were prepared by a double emulsion solvent eva-
poration method as described earlier [20]. To prepare the ﬁrst water-in-
oil (W/O) emulsion, either 75 µl OVA solution (20mg/ml) for in vitro
studies (OVA-NP) or 18.8 µl OVA (40mg/ml), 75 µl poly(I:C) (46.7mg/
ml) and 10 µl rhodamine-labelled poly(I:C) (100 µg/ml) for immunisa-
tion studies (OVA-PIC-NP) were mixed with 1ml of PLGA dissolved in
ethyl acetate (25mg/ml) by tip sonication (15 sec, 20W, Branson so-
niﬁer 250, Danbury, CT, USA). For visualisation or quantiﬁcation stu-
dies, 20% of OVA was replaced with OVA-AF647 or 100% of OVA was
replaced with OVA-IR800, respectively. Next, 2 ml of 2% PVA 4–88
(31 kDa) solution was dispersed with the W/O emulsion by using tip
sonication (15 sec, 20W) to obtain a W/O/W double emulsion. Sub-
sequently, this emulsion was dropwisely added to the 25ml of 0.3% (w/
v) PVA extraction medium (40 °C) under stirring. Next, the ethyl acetate
was evaporated by using a rotavapor (Buchi rotavapor R210, Switzer-
land) for 3 h (40 °C, 150mbar). Then the NPs were collected by cen-
trifugation (AvantiTM J-20XP centrifuge, Beckman Coulter, Brea, CA)
at 35,000g for 10min and washed twice with water. Finally, PLGA NPs
were dried in an ice condenser (Christ Alpha1-2, Osterode, UK) in
freeze vacuum (−49 °C, 90 mbar) overnight and stored at−20 °C until
use.
2.3. PLGA nanoparticle characterisation
Dynamic light scattering (DLS) (ZetaSizer Nanoseries ZS system,
Malvern instruments, Worcestreshire, UK) equipped with a He-Ne laser
(633 nm) was used to measure size and polydispersity index (PDI) of the
NPs dispersed in pH 7.4 PBS (140mM NaCl, 16 mM Na2HPO4, 2.9 mM
KH2PO4, 5.5mM KCl). The zeta potential was measured by laser
Doppler electrophoresis (ZetaSizer Nanoseries ZS system) and samples
were dispersed in HEPES buﬀer (5 mM, pH 7.4).
To determine OVA and poly(I:C) loading of the NPs, 1 mg dried
nanoparticles were dispersed in 0.15ml DMSO and incubated for 1 h at
37 °C. Next, 0.85ml (determination of OVA) or 0.35ml (determination
of poly(I:C)) of 0.05M NaOH with 0.5% (w/v) SDS was added to
samples which were thereafter incubated for an additional 1 h at 37 °C.
The calibration curves were prepared in mixtures of DMSO and NaOH/
SDS. Micro BCA™ protein assay (Pierce Micro BCA™ protein Assay kit,
ThermoFisher, Rockford, IL, USA) was used to measure the OVA con-
centration following the manufacturer’s instructions and absorbance
was determined with a Tecan inﬁnite M1000 plate reader (Tecan
Austria GmbH, Grödig, Austria). To analyse of poly(I:C) concentration,
ﬂuorescence of rhodamine-labelled poly(I:C) was measured by using
the plate reader (λex 545 nm/λem 576 nm).
The encapsulation eﬃciency (EE) and loading capacity (LC) of OVA
and poly(I:C) in the nanoparticles were calculated as below:
= ×
M
M
EE % 100%loadedOVA poly I C
totalOVA poly I C
/ ( : )
/ ( : ) (1)
= ×
+ +
M
M
LC % 100%loadedOVA poly I C
NP OVA poly I C
/ ( : )
( : ) (2)
where Mloaded OVA/poly(I:C) represents the mass of loaded OVA or poly
(I:C), Mtotal OVA/poly(I:C) is the total amount of OVA or poly(I:C) added to
the formulations and MNP+OVA+poly(I:C) is the total weight of NPs, OVA
and poly(I:C).
J. Mönkäre et al. European Journal of Pharmaceutics and Biopharmaceutics 129 (2018) 111–121
112
2.4. Dissolving microneedle preparation
The preparation scheme of the dissolving PLGA NP-loaded MNs is
presented in Fig. 1. PDMS molds were prepared from silicon MN arrays
(16 MN tips in 5.4× 5.4mm array, length 300 µm) as described earlier
[24]. First, HA was dissolved overnight in 10mM phosphate buﬀer
(5.8 mM Na2HPO4, 4.2 mM NaH2PO4, pH 7.0). On the next day, NPs
were suspended in buﬀer and HA solution and NP suspension were
mixed so that the ﬁnal concentrations of NPs and HA were 10mg/ml
and 10mg/ml (NP:HA weight ratio 1:1), 5 and 20mg/ml (NP:HA
weight ratio 1:4) and 5mg/ml and 50mg/ml (NP:HA weight ratio
1:10), respectively. When MNs were visualized with ﬂuorescence mi-
croscopy 1% of total HA was replaced with FAM-HA that was prepared
as described earlier [24]. Next, 30 µl NP:HA mixture was pipetted into
each array of the PDMS mold that was placed in the vacuum for 10min
to remove any entrapped air from the mixture (Fig. 1). To deposit the
nanoparticles into the MN tips, the mold was placed into a centrifuge
(Beckman Coulter Allegra X-12R Indianapolis, IN, USA) for 15min at
3270g. After the centrifugation, the excess mixture (20–25 µl) was re-
moved from the mold, and the remaining mixture was dried for 30min
in a vacuum desiccator at room temperature to evaporate the water.
First four steps were repeated once by adding again NP:HA mixture
(20 µl) into each array of PDMS, followed by centrifugation, removal of
the excess mixture and drying. Subsequently, 60 µl of 50mg/mL HA
solution was added to form an additional HA layer, followed by cen-
trifugation (30min, 930g). Finally, the PDMS mold was dried overnight
in a vacuum desiccator at room temperature. After the complete drying,
a vaccine-free backplate was prepared for all MNs. A mixture of vi-
nylpolysiloxane base and catalyst was prepared and it was added to
each array to form the backplate [25]. MNs were stored at room tem-
perature in a desiccator until use.
For in vivo studies, MNs containing only free OVA and poly(I:C)
(free-OVA-PIC) were prepared, as follows: 60 µl solution containing HA
(40mg/ml), OVA (10mg/ml) and poly(I:C) (10mg/ml) was added to
each array of the PDMS mold. This was placed in vacuum to remove any
air and then centrifuged for 2 h at 3270g. After the centrifugation, an-
other 60 µl of HA/OVA/poly(I:C) solution was added in arrays of the
mold followed by the repetition of the centrifugation step. MNs con-
taining 50% of the OVA and poly(I:C) dose encapsulated in NPs and
50% in free form (free-OVA-PIC/NP mixture) were prepared similarly
to NP-loaded MNs but with some modiﬁcations. Free OVA (5 mg/ml)
and poly(I:C) (5 mg/ml) were mixed to form the mixture for prepara-
tion of MN tips with HA (20mg/ml) and subsequently NPs (2.5 mg/ml)
were added to this mixture. The HA solution for backplate contained
OVA (5mg/ml) and poly(I:C) (5 mg/ml). Subsequently, the samples
were dried overnight in a vacuum desiccator at room temperature.
Finally, the vinylpolysiloxane backplate was prepared as described
above.
2.5. Microscopic analysis of microneedles
The shape of MNs after the preparation and after the immunisation
experiments were analysed by light microscopy (Zeiss, Sterni 2000 C,
Carl Zeiss Microscopy GmbH, Göttingen, Germany). Scanning electron
microscopy (SEM, NOVA nanoSEM, Eindhoven, the Netherlands) was
used to examine additionally the shape, and external and internal
surface morphology of the MNs. The arrays were coated with a platina/
palladium layer to increase the surface conductivity. Images were taken
at magniﬁcations of 31–15,000× by using a voltage of 15 kV between
the electron gun and the sample surface.
The distribution of the NPs containing OVA-AF647 in MNs with
FAM-HA were analysed with ﬂuorescence microscopy (Zeiss Imager D2,
camera AxioCam MRm, light source HXP120V, Carl Zeiss Microscopy
GmbH, Göttingen, Germany) before and after dissolution in the ex vivo
human skin. ZEN Pro 2012 software (Carl Zeiss Microscopy GmbH) was
used for imaging and image analysis in light and ﬂuorescence micro-
scopy.
2.6. Reconstitution of PLGA nanoparticles after microneedle dissolution
To examine whether the various steps of MN preparation inﬂuence
the release of the NPs from the MNs upon the MN dissolution, asym-
metrical ﬂow ﬁeld-ﬂow fractionation (AF4) was utilized. The following
samples were prepared: (1) NP suspension, (2) NP suspension with HA,
(3) NP suspension with HA dried at +37 °C in ambient pressure, (4) NP
suspension with HA dried at room temperature in vacuum and (5) NP-
loaded MNs without silicone backplate. In all samples the NP:HA
weight ratio was 1:4 and 10% of total HA was replaced with FAM-HA.
After drying samples 3 and 4, and 5 on the ﬂat PDMS surface or in
PDMS mold, respectively, they were dispersed and dissolved in PBS (pH
7.4) overnight at +37 °C. Before the analysis, all samples were diluted
to a concentration of 1mg/ml NPs and 4mg/ml HA in PBS.
The AF4 measurements were performed on an Agilent 1200 system
(Agilent Technologies, Palo Alto, CA, USA) combined with Wyatt
Eclipse detectors (Wyatt Technology Europe GmbH, Dernbach,
German). For the separation of NPs and HA, a small channel equipped
with a 350 µm spacer of medium width and a regenerated cellulose
membrane with a cut-oﬀ of 5 kDa were used. Multiangle laser light
scattering (MALLS) was used for the detection of the NPs and the
ﬂuorescence signal (λex 496 nm, λem 520 nm) for the FAM-HA. The
mobile phase was 200mM NaNO3 with 0.02% NaN3, ﬁltered through a
0.1 µm ﬁlter. The injection volume was 20 µl per sample and the de-
tector ﬂow was 1ml/min. The cross-ﬂow was initially set to 0.3ml/min
which was gradually decreased to 0.1 (from 9 to 12min), and set at
0.1 ml/min until 32 min thereafter to 0ml/min as indicated in Fig. 4A.
The fractions were collected at 16–21min and the particle size of the
NPs of the fractions were measured with DLS as described above.
2.7. In vitro quantiﬁcation of PLGA NPs and free OVA content of dissolving
MNs
For this experiment, MNs were prepared as described above except
that NP-loaded MNs contained NPs encapsulating OVA-IR800 and for
OVA MNs 5% of the total OVA was replaced with OVA-AF647. Each
array (n=9 and n=6 for NP and OVA-loaded MNs, respectively) was
dispersed in 1ml of PBS (pH 7.4) for 2 h and the NP and OVA content
was determined with a Tecan plate reader based on the ﬂuorescence of
OVA-IR800 (λex 779 nm, λem 794 nm) and OVA-AF647 (λex 650 nm,
λem 668 nm), respectively.
2.8. Dissolving MN penetration and dissolution in ex vivo human skin
Ex vivo human skin was used to analyse the penetration and dis-
solution of dissolving MN in the skin. Within 24 h after the skin was
obtained from the hospital, excess fat was removed and the skin was
Fig. 1. Preparation scheme of NP-loaded dissolving MNs.
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frozen and stored at −80 °C until use. Upon use, the skin was thawed
and ﬁxed on the Styrofoam. The MNs were applied onto the skin by
using an in-house developed impact-insertion applicator [26] by at-
taching MN array to the applicator head with double-sided tape before
application to the skin.
In the case of skin piercing studies, after inserting MNs into the skin
for 15 s, 50 µl of 0.4% (w/v) trypan blue solution was applied onto the
skin surface for 30min [24]. After the removal of trypan blue solution,
the skin was cleaned with MQ water to avoid visualization of trypan
blue at the skin surface, and ﬁnally the stratum corneum was removed
by tape stripping (∼10 strips) by using normal oﬃce tape. The skin
piercing indicated by blue spots was visualised with a light microscope
(Zeiss, Sterni 2000 C) and the penetration eﬃciency was calculated
diving the number of the successful piercings with the total number of
tips (i.e. 16) in each MN array.
For dissolution studies, MNs were applied onto the skin for 20min
as described for penetration studies. After withdrawal, the MNs were
analysed with a ﬂuorescence microscope. To examine the deposition of
NPs and HA into the skin, this was analysed after MN dissolution with
confocal laser scanning microscopy as described previously [24].
Brieﬂy, the experiment was carried out with a Nikon T-200-e inverted
microscope supplied with a Nikon C1 confocal unit. For acquisition and
analysis of scans, a Nikon Plan Apo 4 × (numerical aperture 4) ob-
jective and Nikon NIS Elements version 4.20.00 64-bit software were
used. The xy resolution was 6.3 µm/pixel and xy scans were acquired
every 10 µm, and rhodamine-labelled trimethyl chitosan (TMC) [27]
was used to determine the skin surface during the analysis. NPs (i.e.
AF647-OVA in NPs) and FAM-HA were visualised with a 637 nm (diode
laser, intensity 75 and gain 100) and a 488 nm (Ar laser, intensity 75
and gain 100) laser, respectively.
2.9. Animals
Balb/c mice (haplotype H2d, female, age 7–8weeks) and C57BL/6
mice (CD45.2+, H2b, age 8 weeks) were purchased from Charles Rivers
(Maastricht, The Netherlands). They were housed under standardised
conditions in the animal facility of Leiden Academic Centre for Drug
Research of Leiden University. Experiments were approved by the
ethical committee on animal experiments of Leiden University (licence
number 14241).
2.10. Quantiﬁcation of the delivered dose by dissolving microneedles in vivo
Dissolving MNs containing NPs encapsulating IR800-OVA or free
IR800-OVA were used to quantify amount of delivered OVA-NPs and
OVA in the skin, respectively. First, balb/c mice were anaesthetised by
intraperitoneal injection of ketamine (60mg/kg) and xylanize (4 mg/
kg) and the insertion site was shaved. Next, MNs were applied on by
using an impact-insertion applicator for 20min, as described above
(Section 2.8). The calibration standards were injected with a hollow
MN applicator as described below (Section 2.11) in shaved ex vivo
mouse skin by using either free IR800-OVA (63–1000 ng protein/in-
jection) or IR800-OVA-NPs (0.625–20 µg NPs/injection). The variation
of injected amount of OVA or NPs was achieved by varying the injection
volume (0.31–10 µl). Mice were sacriﬁced before measuring the ﬂuor-
escence intensity by using a Perkin-Elmer IVIS Lumina Series III in vivo
imaging system (Waltham, MA, USA) with an excitation wavelength of
745 nm and an emission ﬁlter set at ICG. Other parameters were set as
follows: acquisition time 8 s, F-stop 2, binning 4 and ﬁeld of view of
12.5 cm. Perkin-Elmer Living Image software version 4.3.1.0 was used
for image acquisition and analysis. Untreated sites of the skin were used
to determine the background signal.
2.11. Immunisation study for antibody responses
Study groups (n=8/group) were immunised either by intradermal
injection with hollow MNs or 20min insertion of dissolving MNs on the
ﬂank of the mice. Hollow MNs were fabricated by hydroﬂuoric acid
etching from fused silica capillaries and injections were performed with
an in-house developed applicator as described earlier [20,28,29]. The
bore diameter of the hollow MNs was 50 µm, the injection depth
200 µm, the injection rate 12 µl/min and the injection volume 12 µl.
Before the immunisation, mice were anaesthetised by intraperitoneal
injection of ketamine (60mg/kg) and xylanize (4 mg/kg) that was
followed by the shaving of the immunisation site. In all study groups,
the total dose of both OVA and poly(I:C) doses were ∼1 µg. Three
diﬀerent formulations were used and they were administered with both
hollow and dissolving MNs: 1) free-OVA-PIC, 2) mixture of free-OVA-
PIC (50% of dose) and OVA-PIC-NPs (50% of dose), and 3) OVA-PIC-
NPs. The buﬀer with low ion concentration (10mM phosphate buﬀer,
pH 7.0) was used to dissolve OVA and poly(I:C), and to suspend NPs to
prevent a premature release from NPs. Mice were immunised on the day
0 (prime), day 21 (1st boost) and day 42 (2nd boost), and before each
immunisation venous blood sample was collected from the tail to
measure the antibody responses. Mice were sacriﬁced on day 51 by ﬁrst
collecting a blood sample from abdominal/thoracic vein followed by
cervical dislocation.
2.12. ELISA analysis of OVA-speciﬁc IgG antibodies
OVA-speciﬁc antibodies were analysed by a sandwich enzyme-
linked immunosorbent assay (ELISA) as described earlier [20]. The
plates (Nunc-Immuno MaxiSorp 96, ThermoScientiﬁc, Roskilde, Den-
mark) were coated with 500 ng of OVA for 1.5 h at 37 °C in 0.05M
carbonate/bicarbonate buﬀer (pH 9.6), followed by the blocking step
with 1% (w/v) BSA in PBS (1 h at 37 °C). Next, diluted sera of each
mouse was further serially diluted three-fold with dilution buﬀer (PBS
with 0.5% BSA and 0.05% Tween 80) and incubated for 1.5 h at 37 °C.
Subsequently, 1:5000 diluted horseradish peroxidase-conjugated goat
antibodies against IgG, IgG1, IgG2a were added to the plates to be in-
cubated for 1.5 h at 37 °C. Finally, antibodies were detected by adding
TMB and after 15min, the reaction was stopped with 2M H2SO4. The
absorbance was measured at 450 nm and the antibody titre was de-
termined as a log10 value of the mid-point dilution of S-shaped dilu-
tion-absorbance curve of the diluted serum level.
2.13. Immunisation study for transgenic CD4+ and CD8+ T-cell responses
One day before the immunisation, CD8+ T cells (OT-I, CD45.1+)
and CD4+ T cells (OT-II, CD45.1+) were obtained from transgenic mice
as described recently [20]. An equivalent 20 000 OT-I and 200 000 OT-
II cells were adoptively transferred in the C57BL/6 mice (CD45.2+,
H2b) by i.v. injection in 200 µl PBS. On the following day, mice (n=4/
group) were immunised with OVA-PIC-NPs (OVA and poly(I:C)
doses∼ 4 µg) either delivered by using four dissolving MN arrays per
mouse or hollow MNs as described above. PBS was injected by hollow
MNs for the negative control group (n= 3). At day 7, mice were sa-
criﬁced by cervical dislocation and spleens were collected to isolate
splenocytes for ﬂow cytometry analysis.
2.14. Flow cytometry analysis of CD8+ and CD4+ T-cells
Splenocytes were isolated from the collected spleens by using 70 µm
Nylon cell strainers (Falcon, Corning, Corning, NY, USA) followed by
30 s lysis of erythrocytes by using Ammonium-Chloride-Potassium
(ACK) lysis buﬀer. Thereafter, the splenocytes were washed with PBS
and cell suspension (∼500 000 cells per well) was added to the 96-well
plate. After the washing of the cells, the cell surfaces were stained with
ﬂuorescently labelled antibodies against CD45.1 (eﬂuor450, 1:800 di-
lution), CD4 (APC, 1:800), CD8α (PE, 1:800) and Thy1.2 (PE-Cy7,
1:400) in 100 µl of FACS buﬀer. After 30min incubation at +4 °C, the
excess antibodies were washed by FACS buﬀer before the incubation
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with Cytoﬁx solution (BD Bioscience) for 10min at 4 °C. Before the ﬂow
cytometry analysis (FACS CantoII, BD Biosciences), the cells were wa-
shed once with FACS buﬀer. The data were analysed by using FlowJo
software (version 10.0.7. TreeStar Inc).
2.15. Statistical methods
Statistical diﬀerences in immunisation studies were analysed by 1-
way ANOVA with Bonferroni’s multiple comparison post-test
(GraphPad Prism version 5.02). The data of DLS analysis of AF4 frac-
tions was analysed by Kruskall-Wallis test followed by Dunn’s multiple
comparison test. The level of the signiﬁcance was set at 0.05 in both
cases.
3. Results
3.1. Development and characterisation of PLGA NP-loaded dissolving MNs
PLGA NPs were loaded with OVA (OVA-NP) for MN development
and characterisation studies, and with OVA and poly(I:C) (OVA-PIC-
NP) for immunisation studies. The NPs had a size, determined by DLS
and expressed as Z-average diameter, between 150 and 200 nm and
their zeta potential was negative (Table 1). The co-encapsulation of
poly(I:C) did not signiﬁcantly aﬀect these values. The OVA loading
capacity in OVA-NPs was 7.7% w/w and the encapsulation eﬃciency
was 67%. When OVA and poly(I:C) were co-encapsulated, their loading
capacities were 3.2% and 3.0% (w/w), respectively, and thus the
weight ratio of their encapsulated doses was approximately 1:1. The
diﬀerence in OVA loading capacity between OVA-NPs and OVA-PIC-
NPs was probably due to adjustment of initial amount of OVA in order
to obtain equal loading capacity of OVA and poly(I:C). The en-
capsulation eﬃciencies of OVA and poly(I:C) in OVA-PIC-NPs were
53% and 10%, respectively.
HA-based dissolving MNs containing antigen and adjuvant loaded
NPs were successfully developed. Preliminary studies indicated that
sharp MNs with very high NP content could be produced without ad-
ditional HA as matrix material in the MN tips (data not shown).
However, these MNs did not have suﬃcient mechanical strength for
reproducible skin penetrations. Consequently, it was decided to mix
varying concentrations of HA solution with the NP suspension to study
which compositions result in the formation of MNs with suﬃcient
strength and sharpness for skin penetration. The examined weight ra-
tios of NP:HA were 1:1, 1:4 and 1:10. During the preparation, the ﬁrst
four preparation steps was repeated once to increase the number of NPs
deposited into the MN tips and consequently to increase the dose de-
livered into the skin (Fig. 1). All MNs (containing NPs, free-OVA-PIC/
NP mixture, or free-OVA-PIC) had equal dimensions (length 300 µm)
and sharpness (Fig. 2).
To minimize wastage of vaccine and increase the delivered dose, it is
crucial that NPs are localized in the MN tips and minimally in the backplate.
As can be inferred from SEM (Fig. 2) and ﬂuorescence imaging (Fig. 3), the
NPs were mainly concentrated in the tips of the MNs. SEM images showed
that the upper parts of the MN tips had rough surfaces (Fig. 2A–C) in
contrast to smooth surfaces of MNs with free-OVA-PIC (Fig. 2E), suggesting
the localization of NPs into the MN tips. Additionally, ﬂuorescence micro-
scope images showed that low HA concentrations (10 or 20mg/ml, with a
NP:HA weight ratio of 1:1 and 1:4, respectively) allowed the eﬃcient de-
position of NPs into the MNs tips. This is indicated by the yellow colour of
the MN tips, resulting from overlay of OVA-AF647 loaded NPs (red label)
and FAM-HA (green label) (Fig. 3A and C). Furthermore, ﬂuorescence mi-
croscope images suggested that the NP content of MN tips was relatively
uniformly distributed between diﬀerent MN tips with 1:4 and 1:1 NP:HA
ratios (Fig. 3A and C). In contrast, a high HA concentration (50mg/ml) with
1:10 NP:HA ratio seems to prevent the homogenous NP distribution in the
MN tips or backplate (Figs. 2C and 3E) due to the high viscosity caused by
the elevated HA concentration. Finally, SEM images of cross-sections cut at
the approximate half-height of MN tips were analysed. The comparison of
the cross-sections of OVA-loaded and NP-loaded MNs indicated the presence
of NPs in the HA matrix of NP-loaded MNs (Fig. 2G–H). Spherical shapes of
NPs could be detected in the cross-sections of NP-loaded MNs, while OVA-
loaded MNs had smooth cross-section surface.
After NP-loaded MNs have been applied into the skin, they should
be able to release the NPs in non-aggregated form. Since it would be
very diﬃcult to study the particle size of NPs released in situ in skin, we
decided to dissolve the MNs in PBS instead and analysed the size of the
released NPs by AF4 and DLS. As the NP:HA 1:4 ratio had the most
optimal characteristics concerning NP distribution and dissolution in
the skin (see next Section 3.2), we selected this ratio for the experi-
ments. AF4 was used to separate FAM-labelled HA and (unlabelled) NPs
and analyse the samples with online ﬂuorescence and MALLS detection,
respectively. Based on the MALLS signal, it was selected which fractions
were collected from AF4 analysis to measure NP size oﬄine with DLS.
In addition, the MALLS signal was used to compare the relative
amounts of particulate material in AF4 elugrams between diﬀerent
samples prepared with same NP batches [30]. However, there are
limitations in the use of MALLS signal since it is aﬀected not only by
particle concentration but also by the particle size. Alternatively, re-
fractive index signal could be used but in this study the signal was too
weak for meaningful analysis.
First, the ﬂuorescence signal of FAM-labelled HA was similar in all
samples containing NPs, suggesting that diﬀerent drying conditions did
not aﬀect HA dissolution (Fig. 4A). HA without NPs had the elution
peak maximum at 9min but in the presence of NPs the elution peak
shifted to 12min. However, the elution peaks of samples containing
NPs had shoulder at 9min. This indicates that in samples containing
NPs, a part of HA is in original form while other part of HA was weakly
interacting with NPs. As expected, the NP suspension showed a prac-
tically ﬂat ﬂuorescence baseline.
According to the MALLS signal, the NPs started eluting at 12min.
Thus, it was not overlapping with the elution of HA, and additionally
HA did not show a measurable MALLS signal (cf. Fig. 4A and B). The
MALLS signal was high for non-dried NP control samples, i.e., NP sus-
pensions with and without HA, but the presence of HA slightly delayed
the elution of NPs (Fig. 4B), conﬁrming the presence of interaction
between the NPs and HA. NP:HA samples dried in a vacuum desiccator
at room temperature had a high and similar MALLS signal to that of
Table 1
Physicochemical properties and OVA and poly(I:C) loading characteristics of OVA-NPs (mean ± SD, n=4) used for in vitro studies and OVA-PIC-NPs (n=5) used in
immunisation studies.
Formulation Size (nm)a PDI Zeta potential (mV) OVA LCb (% w/w) Poly (I:C) LCa (% w/w) OVA EEc% Poly(I:C) EEc %
OVA-NP 187 ± 31 0.25 ± 0.05 −18.1 ± 4.4 7.7 ± 0.4 N/A 66.7 ± 3.5 N/A
OVA-PIC-NP 160 ± 12 0.16 ± 0.03 −12.0 ± 4.6 3.2 ± 0.9 3.0 ± 2.2 53.3 ± 10.7 10.5 ± 6.7
N/A=not applicable.
a Z-average.
b loading capacity.
c encapsulation eﬃciency.
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(freshly prepared) NP:HA suspension. In contrast, NP:HA mixtures
dried at 37 °C in ambient pressure showed a low MALLS signal upon
reconstitution in PBS. These ﬁndings suggest that vacuum drying leads
to minimal NP aggregation, whereas drying at ambient pressure con-
ditions leads to substantial NP aggregation. This aggregation was also
visually observed by the presence of precipitated material at the bottom
of the sample vial. Next, the MALLS signal of dispersed MN samples
largely overlapped with that of vacuum dried samples, suggesting the
presence of dispersed NPs. However, the elution of NPs was delayed
compared to the vacuum dried sample. Furthermore, when the cross-
ﬂow was stopped at 32min, a higher amount of NPs or alternatively
some very large of non-eluted particles were ﬂushed out of the channel
in comparison to vacuum dried samples. These observations suggest
that eluted NPs in MN samples had a larger hydrodynamic diameter
than NPs in the vacuum dried samples, which can be considered as an
indication of the formation of NP aggregates. However, as mentioned
above, the results indicate transient HA-NP complexes dissociating
during the analysis, and not strong interactions between HA and NP.
DLS analysis of collected NP fractions from AF4 corroborated the
above-presented AF4-MALLS results (Table 2). Compared to AF4-
MALLS, DLS allows a more accurate quantiﬁcation of the particle size.
Mixing of HA solution and NPs did not aﬀect the particle size of the
NPs. Vacuum drying increased the particle size and PDI of the NPs only
slightly (201 nm, 0.27), but after drying at ambient conditions (at
37 °C), the light scattering signal was very low and no meaningful DLS
results could be obtained. This latter observation indicates a low con-
centration of NPs in the samples. In dispersed NP-loaded MN samples,
the NP size and PDI, and were higher (287 nm, 0.35) than that of va-
cuum dried samples (201 nm, 0.27), and additionally the variation
between separate experiments was larger as indicated by larger SD. This
suggests that NPs were more aggregated in MN samples than in vacuum
dried samples. This could be due to the centrifugation step during the
MN preparation. Centrifugation does force NPs into the microcavities of
the PDMS mold and this may have caused the NP aggregation.
Fig. 2. SEM images of, single tips of MNs with 1:1 (A), 1:4 (B) and 1:10 (C) NP:HA ratios, and MN tips of free-OVA-PIC/NP mixture (D) and free-OVA-PIC (E), full
array of NP-loaded MN 1:4 NP:HA ratio (F), and cross-sections of NP-loaded MNs (1:4 ratio) (G) and free-OVA-PIC (H) MNs. Scale bars are 50 µm (A-E), 1mm (F),
1 µm (G) and 2 µm (H).
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3.2. Dissolving MN piercing and dissolution in ex vivo human skin
Dissolving MNs need to have suﬃcient mechanical strength to pe-
netrate into the skin and therefore their penetration into ex vivo human
skin was examined by using a trypan blue assay. The skin penetration
eﬃciency indicates the percentage of MN tips successfully penetrated
into the skin and it was 91.9 ± 1.6% (n=10), 100% (n=6) and
85.4 ± 2.5% (n=3) for MNs with NP:HA 1:1, 1:4 and 1:10 wt ratios,
respectively (Fig. 5A). This experiment showed an excellent skin pe-
netration eﬃciency for the diﬀerent arrays, and especially for the MNs
with a NP:HA weight ratio of 1:4.
Dissolution of the MNs with NP:HA ratios of 1:1, 1:4 and 1:10 was
examined by assessing MN tips with microscope after the application
into the ex vivo human skin. The NP:HA ratio remarkably inﬂuenced the
dissolution of MN tips. For MNs with a NP:HA ratio of 1:1, the dis-
solution rate was slow and no signiﬁcant dissolution occurred within
20min (Fig. 3B). Importantly, the dissolution rate was clearly improved
for MNs with 1:4 and 1:10 NP:HA ratios (Fig. 3D and F) and thus, an
increase of HA content facilitated the MN dissolution. Finally, the skin
was analysed with confocal microscopy immediately after the MNs
were inserted and left for 20min in the skin. The results showed that
both the HA and the NPs were deposited into the ex vivo human skin
until an approximate depth of 200–300 µm (Fig. 5B and C). Based on
the results regarding the preparation of MNs and their dissolution, MNs
with a NP:HA ratio of 1:4 were selected for in vivo studies.
3.3. Dissolution rate and delivered antigen dose of dissolving MNs in mice
The MN dissolution rate and antigen dose delivered into the skin
were characterised in vivo in mice after administering dissolving MNs
containing NPs (NP:HA ratio 1:4) loaded with OVA-IR800. The MNs
were applied into the skin of mice (n=4) and left in the skin for 20min
Fig. 3. NP-loaded MN arrays imaged with ﬂuorescence microscopy before (A, C and E) and after 20min (B, D and F) application into ex vivo human skin. Results for
MN arrays prepared with NP:HA ratios of 1:1 (A-B), 1:4 (C-D) and 1:10 (E-F) are shown. Green, red and yellow colours indicate HA, OVA-AF647 loaded NPs and their
co-location, respectively. The scale bar is 1 mm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 4. AF4 elugrams of (A) FAM-labelled HA (measured by ﬂuorescence) and
(B) PLGA NPs (measured by MALLS) of dissolved MN sample and control
samples. Both signals were recorded simultaneously but for sake of clarity the
data is presented in two panels. In panel A, the crossﬂow proﬁle is indicated by
the dashed line (right y-axis) and in panel B, the period during which the NP
fraction was collected for DLS analysis is indicated. All NP:HA samples had a
weight ratio of 1:4 and samples are described in detail in Section 2.7. One
representative set of elugrams from three independent experiments is pre-
sented. Legend in panel B as presented in panel A.
Table 2
Z-average diameter and PDI (mean ± SD; n= 3–4) of fractions collected from
AF4 analysis (16–21min, see Fig. 4) and measured with DLS. All NP:HA sam-
ples had weight ratio of 1:4 and samples are described in detail in Section 2.7.
Sample Z-average (nm) PDI
NP suspension 174 ± 17 0.190 ± 0.077
NP:HA suspension 169 ± 12 0.228 ± 0.065
NP:HA (vacuum dried) dispersed in PBS 201 ± 34 0.272 ± 0.057
NP:HA (dried at 37 °C) dispersed in PBS > 1000*** 0.613 ± 0.292**
NP-loaded MNs dissolved/dispersed in PBS 287 ± 130* 0.350 ± 0.148
* p < 0.05 diﬀerence to NP:HA suspension.
** p < 0.01.
*** p < 0.001.
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by using an impact-insertion applicator, similarly to the experiments
with ex vivo human skin. The delivered dose of antigen was quantiﬁed
by near-IR imaging [23]. Hollow MN injections of OVA-IR800 loaded
NPs were used for calibration, since the encapsulated OVA-IR800 had a
signiﬁcantly lower ﬂuorescence signal than OVA-IR800 solution. NP-
loaded MNs delivered 31.0 ± 14.3 µg (n= 7, mean ± SD) NPs into
the mice, which corresponds to 0.99 ± 0.46 µg OVA and
0.93 ± 0.43 µg poly(I:C) based on loading capacities of OVA-PIC-NPs
used for immunisation studies (Table 1). When the delivered dose of
NPs was compared to NP content of total MN array (130 ± 25 µg,
n=9, mean ± SD) measured in vitro, it was found that 24% of the
dose contained in NP-loaded MN arrays was actually delivered into the
skin.
In the case of MNs containing free-OVA, injections of free OVA-
IR800 were used for calibration. These MNs delivered 1.02 ± 0.52 µg
(n=5, mean ± SD) OVA into the mice. The delivered poly(I:C) dose
was not measured, but is expected to be approximately 1 µg based on
the OVA:poly(I:C) ratio of 1:1 in the MNs. OVA-loaded MN arrays
contained totally 652 ± 57 µg (n=6, mean ± SD) OVA based on in
vitro dissolution experiment. Consequently, only 0.16% of the total OVA
in a MN array was delivered into the skin. Therefore, it can be con-
cluded that NP-loaded MNs had much higher delivery eﬃciency into
the skin than free-OVA loaded MN arrays, and that the wastage of the
payload was moderate in NP-loaded MNs. Nevertheless, it must be
noted that a part of the antigen is lost during the NP fabrication since
the encapsulation eﬃciency is not 100%. For MNs containing a mixture
of free OVA and NPs, it was assumed that MNs would have a similar
delivery eﬃciency of NPs and free-OVA as MNs containing solely NPs
or free-OVA.
3.4. Immunisation studies
Mice were immunised with OVA-PIC-NPs, a solution of OVA and
poly(I:C) (free-OVA-PIC), or a 1:1 mixture of OVA-PIC-NPs and free-
OVA-PIC administered either by dissolving MNs or a hollow MN. The
major diﬀerence between these two immunisation methods is that a
hollow MN delivers a known volume of either vaccine solution or
suspension [20], whereas dissolving MNs are solid formulations re-
quiring dissolution and release of vaccine.
All dissolving MN arrays were characterised by light microscopy
after the immunisations studies (Fig. 6). These analyses conﬁrmed
that> 95% of applied arrays could dissolve suﬃciently to deposit the
MN tip containing NPs or free-OVA-PIC into the mice. Furthermore, the
visual analysis of MNs after the immunization did not reveal any sub-
stantial diﬀerences between the dissolution of MNs containing (1) OVA-
PIC-NPs, (2) free-OVA-PIC or (3) a mixture of these two.
In the case of immunization with soluble free-OVA-PIC, delivery
with dissolving and hollow MNs resulted in comparable IgG1 and IgG2
responses (Fig. 7). When 50% of the OVA dose was in soluble form and
the other 50% of the OVA loaded in NPs, hollow MN mediated delivery
tended to evoke higher OVA speciﬁc IgG1 and IgG2a responses than
dissolving MN mediated delivery, although no statistical diﬀerences
were found. When the whole OVA dose was encapsulated in NPs,
hollow MN mediated delivery resulted in statistically stronger IgG1
responses than NP-loaded dissolving MNs at all time points (Fig. 7). In
addition, strong IgG2a response was detected after hollow MN-medi-
ated delivery of NPs but not after the dissolving MN-mediated delivery.
Moreover, in line with our previous results [20], encapsulation of OVA
and poly(I:C) in NPs did not improve the IgG1 response, but was re-
quired for eliciting a robust IgG2a response after hollow MN mediated
immunisation (Fig. 7D–F). An increased IgG2a response after NP vac-
cination suggests triggering of cellular immune responses. Therefore,
CD8+ and CD4+ T-cell responses were analysed by using adoptive
transfer of transgenic OT-I and OT-II cells before the delivery of the
OVA-PIC-NPs by dissolving and hollow MNs. Hollow MN mediated
delivery of NPs resulted in robust CD8+ and CD4+ T-cell responses
(Fig. 8). In contrast, dissolving MN mediated delivery resulted in ab-
sence of a CD8+ response and only a minimal CD4+ response.
4. Discussion
The aim of the study was to develop a dry-state nanoparticulate
vaccine formulation for minimally invasive intradermal immunisation
by using HA-based MNs. The developed MNs should be able to pene-
trate into the skin followed by fast dissolution, and subsequently deliver
a suﬃcient antigen dose in a reproducible manner. Until now, only a
small number of studies have described the use of nano- [17,18,31] or
microparticle [32] -loaded dissolving MNs for intradermal vaccine de-
livery. However, these studies were mainly focused on the analysis of
immunological eﬀects, whereas the understanding of optimal MN for-
mulation parameters is still limited. Therefore, in this study, important
technical aspects of the pharmaceutical development of such a complex
formulation combining NPs and dissolving MNs were explored. The
clinical translation of dissolving MNs for vaccination has been recently
reviewed [4] and it is not further discussed here.
Fig. 5. A representative top view of ex vivo
human skin indicating the penetration of
dissolving MNs (NP:HA ratio 1:4) into the
skin, the scale bar is 1000 µm (A); confocal
microscopy images showing the deposition
of HA in green (B) and NPs in red (C) into ex
vivo human skin after 20min application of
MNs (NP:HA ratio 1:4), with the x- and y-
axis indicating the skin surface, and the z-axis (length 700 µm) the depth of the skin. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
Fig. 6. Light microscopy images of dissolving MN arrays before (A) and after
20min application to mice in immunisation studies: NP- (B), free-OVA-PIC/NP
mixture- (C) and free OVA-PIC- (D) loaded MNs. All formulations dissolved in
vivo in a comparable manner since no MN tips can be detected in panels B-D.
The scale bar is 500 µm.
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The ratio of HA as matrix material and NPs was found to be im-
portant for successful skin penetration and dissolution of MNs. The
optimal NP:HA ratio obtained in this study was 1:4 and this was based
on two observations. First, with a NP:HA weight ratio of 1:1 or 1:4, the
viscosity of HA did not negatively aﬀect MN preparation. In contrast, a
high HA content of the MNs with NP:HA weight ratio 1:10 increased the
viscosity of NP/HA suspension such that the suspension became diﬃ-
cult to handle in the preparation phase. In addition, the higher viscosity
limited the deposition of NPs into the MN tips, as was reported also
recently for PVP/PVA-based MNs [18]. Importantly, this can decrease
the delivered vaccine dose. Secondly, MN dissolution in ex vivo human
skin was strongly inﬂuenced by the NP:HA ratio. Whereas MNs with a
NP:HA weight ratio of 1:4 or 1:10 dissolved within 20min in the skin,
those with a NP:HA ratio of 1:1 hardly dissolved and were therefore
considered unsuitable for eﬀective immunisation. Interestingly, MN
dissolution in mouse skin was more complete than in ex vivo human
skin, probably due to the higher humidity and temperature of the tissue
of the mice. Based on the results of these studies, the dissolving MNs
with a NP:HA weight ratio of 1:4 were selected for in vivo studies.
The centrifugation and drying conditions were found to be critical
for successful MN preparation. Without the optimization of these con-
ditions, it would not be possible to deliver suﬃcient vaccine into the
skin and to ensure the ideal re-dispersion of NPs from dry-state to a
single particle suspension in the skin, both of which are required for an
eﬀective immunisation. First, the centrifugation step was crucial to
increase the delivered antigen dose by at least 100-fold, by depositing
the NPs into the MN tips. This was estimated by comparing the per-
centages of the delivered dose of the total vaccine content of a MN
arrays between free OVA and NP-loaded MNs (0.16% vs. 24%) since
free OVA as solute is not deposited into MN tips by the centrifugation as
occurs for NPs. However, centrifugation bears the risk of potential ag-
gregation of NPs, as indicated in this study by a slight increase of the
particle size and the PDI of the NPs after in vitro dispersion of MN ar-
rays. To study this, it was necessary to develop a novel analysis method
of NP-loaded MNs combining AF4 and DLS, since the analysis with
more straightforward methods (e.g., nanoparticle tracking analysis or
DLS only) were confounded by the presence of HA in the dispersion
medium (data not shown). The application of this developed method is
not limited only for NP-loaded MNs but it is suitable also for other
formulations embedding NPs in matrices. Secondly, besides the cen-
trifugation, the importance of optimal drying conditions for good NP
dispersion after MN dissolution was highlighted in this study. Vacuum-
drying of the MNs during the preparation prevented practically com-
pletely NP aggregation, while drying of the MN arrays at ambient
conditions, that were found to suitable for HA-based protein-loaded
dissolving MNs in our previous study [24], led to severe NP
Fig. 7. IgG1 (A-C) and IgG2a (D-F) responses 21 days after the prime immunisation (A and D), 21 days after the boost (B and E) and 9 days after the second boost (C
and F) administered with hollow MNs (H-MN, grey bars) or dissolving MNs (D-MNs, black bars). Mid-point titres log10 dilutions shown (mean ± SEM, n=8).
*p < 0.05, **p < 0.01, ***p < 0.001.
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aggregation. The superiority of vacuum drying can be attributed a
lower temperature and vacuum at low relatively humidity, which can
decrease interactions between PLGA NPs and consequently suscept-
ibility to the aggregation. However, as some NP aggregation was still
detected after the in vitro dispersion of NP-loaded MNs, there is still
room for further optimization such as by screening excipients or al-
ternative drying methods. For example, freeze drying is generally used
for drying of nanoparticles as dry powder [33] or when embedded in
matrices [34]. Although, in the case of HA, freeze drying produces
sponge-like cakes without suﬃcient mechanical strength for the pene-
tration into the skin, it could be potentially suitable method for other
matrix materials. Finally, it is highlighted that the optimization of
preparation conditions should be performed for each NP and matrix
combination.
Finally, the immunogenicity of dissolving MNs (dry state NPs) was
compared to that of hollow MNs (NP suspension) using identical doses.
The intradermal injection of OVA-PIC-NP suspension elicited strong
cellular and humoral responses, which conﬁrms our recent results
showing the potency of this vaccine formulation [35]. Unfortunately,
the NP-loaded dissolving MNs elicited inferior humoral responses and
lacked cellular responses in comparison to hollow MN mediated im-
munization. However, immunisation with free-OVA-PIC by dissolving
or hollow MN resulted in comparable immune responses, which sug-
gests that the HA-based MNs are able to successfully deliver soluble
antigens and adjuvants intradermally. Administration of a mixture of
free and encapsulated OVA and poly(I:C) in dissolving MNs resulted in
IgG1 responses between those of dissolving MNs containing either free
antigen and adjuvant or antigen and adjuvant encapsulated in NPs. This
supports the ﬁnding that OVA-PIC-NPs in dissolving MNs evoked in-
ferior humoral responses compared to free-OVA-PIC. It is generally
accepted that the nanoparticulate nature of the vaccine is required for
strong T-cell and Th1-type responses since the NP uptake by dendritic
cells is enhanced by small size (< 200 nm) [8,36] leading to co-delivery
of antigen and adjuvant. Therefore, the absence of cellular or IgG2a
immune responses in dissolving MN-mediated immunisation may be
due to the absence or a low number of single NPs in the skin. As the
MNs almost completely dissolved in the skin, our results suggest that
NP-loaded dissolving MNs were unable to release NPs in non-ag-
gregated form in the skin. This is diﬀerent from the in vitro release
analysed with AF4 and DLS. The discrepancy can be related to the
diﬀerences between conditions in vitro and in vivo such as the limited
amount of tissue ﬂuid and low diﬀusivity in the skin as compared to
PBS. Therefore, NP dispersion and distribution in the skin after the
immunisation may be potentially hindered with dry vaccine formula-
tion, such as dissolving MNs, leading to poor vaccine uptake by antigen
presenting cells in comparison to administration of NP suspension.
For future studies, the formulation of dissolving MNs should be
improved to maintain NP integrity upon release into the skin and to
obtain T-cell responses, for instance, by examining suitable excipients
and further optimizing the preparation conditions to enhance NP dis-
persion and distribution in the skin. Alternatively to PLGA NPs and HA,
other MN matrix materials or nanoparticles, such as liposomes [15] and
Fig. 8. Percentage of OVA speciﬁc CD8+(A) and CD4+T-cells (B) in splenocytes 7 days after immunisations with OVA-PIC-NPs shown (mean ± SEM, n=4).
Examples of CD45.1 pre-gated ﬂow cytometry plots after hollow (C) and dissolving MN (D) immunisations are shown.
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nanogels [37,38], or use of antigen-adjuvant conjugates [39,40] could
be examined, and thus more suitable formulations could be discovered.
5. Conclusions
HA-based dissolving MNs loaded with PLGA NP were developed for
minimally invasive intradermal vaccination. The optimal ratio of NPs
and HA in MNs was a critical parameter for MN preparation and dis-
solution in the ex vivo human skin. The importance of the drying con-
ditions in the preparation of dissolving MNs was shown by AF4/DLS
analysis of the NP size after in vitro dispersion of MNs. Intradermal
immunisation with PLGA NP-loaded dissolving MNs was able to evoke
humoral but practically no detectable cellular immune responses,
whereas hollow MN mediated delivery of identical PLGA NPs resulted
in robust humoral and cellular immune response. Finally, these results
are a valuable foundation for the future development of MN-based
delivery of particulate vaccines.
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